diacerein / Generic mfg. - LARVOL DELTA

Coral-YOLO: An Intelligent Optical Vision Sensing Framework for High-Fidelity Marine Habitat Monitoring and Forecasting. (PubMed, Sensors (Basel)) - "Evaluated on our newly curated, multi-year CR-Mix dataset, Coral-YOLO achieves a state-of-the-art 50.3% AP (average precision at IoU threshold 0.5:0.95, following COCO metrics), representing a +1.8 percentage point improvement over the YOLOv12-m baseline, with particularly pronounced gains on small objects (+2.6 percentage points in APS)...Coral-YOLO sets a new performance benchmark and enables proactive reef conservation. It provides a powerful tool to identify at-risk corals long before severe bleaching becomes visually apparent."

Journal

Diacerein ameliorates acute urarthritis in rats through the Nrf-2/HO-1 and NF-κB pathways. (PubMed, Inflammopharmacology) - "The anti-inflammatory, analgesic, and renal protective effects of high-dose diacerein are comparable to those of indomethacin, and its oral administration is convenient, which provides experimental references for the subsequent clinical transformation research of diacerein in acute urarthritis and the development of multi-target anti-gout drugs."

Journal • Preclinical • Gout • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatology • GAPDH • IL1B • IL6 • NFKBIA • RELA • TNFA

Targeting the Galectin Axis in Osteoarthritis: Chondroprotective Effects of Dietary and Pharmacological Phytochemicals. (PubMed, Molecules) - "Our study identifies Brazilin, Diacerein, and Resveratrol as promising modulators of galectin-driven cartilage degeneration and demonstrates the translational potential of patient-derived chondrogenic pellets as a human-relevant platform for preclinical drug evaluation in OA. The 3D culture effectively recapitulates key aspects of OA pathophysiology and offers a robust system to advance therapeutic discovery targeting ECM remodeling."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • COL1A1 • COL2A1 • MMP1 • MMP13 • MMP3

Risk factors for severe knee osteoarthritis and efficacy of diacerein in obese vietnamese patients: A randomized, single-blind, noncontrolled clinical trial. (PubMed, Medicine (Baltimore)) - "Increased waist circumference, plasma TG, and TG/high density of lipoprotein cholesterol ratio raise the risk of severe knee OA. Diacerein treatment improves symptoms and joint function in patients with knee OA accompanied by obesity, with the 100-mg/day dose showing earlier and more effective improvement than the 50-mg/day dose."

Clinical • Journal • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology

Diacerein attenuates sepsis shock mortality through combined suppression of vascular inflammation, stiffness, and permeability. (PubMed, Phytomedicine) - "Diacerein attenuates sepsis shock mortality by concurrently suppressing vascular inflammation via NF-κB and chemokines, improving macrovascular reactivity/ECM remodeling, and reducing microvascular leakage by selectively inhibiting endothelial STAT2 activation. This is the first study to comprehensively demonstrate the efficacy of Diacerein in septic shock through a multi-mechanism vascular strategy and to identify its novel inhibitory effect on the STAT2 pathway in the endothelium."

Journal • Hypotension • Infectious Disease • Inflammation • Septic Shock • CDH5 • COL1A1 • COL3A1 • STAT2 • TJP1

Design and Evaluation of Diacerein-Loaded Oleoliposome Dry-Powder Inhalation Nano-Formulation for Targeted Anti-Inflammatory Therapy in COPD. (PubMed, J Pharm Sci) - "The developed DIA-OL nano-dry powder inhaler (DIA-OL) combines small aerodynamic diameter, high lung deposition, sustained release, and potent anti-inflammatory action, positioning it as a promising non-steroidal, biologic-free inhalation therapy for COPD and related inflammatory lung disorders."

Journal • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL1B • IL6 • NFKBIA

Inflammation and Immune Pathways in Myopia: An Overview on Pathomechanisms and Treatment Prospects. (PubMed, Clin Rev Allergy Immunol) - "Anti-inflammatory agents, including diacerein, resveratrol, and lactoferrin, have demonstrated therapeutic potential in experimental models by modulating inflammatory pathways, reducing pro-inflammatory cytokines, and preserving ECM integrity. However, their clinical efficacy and long-term safety require further validation. Elucidating the complex interplay between inflammation and myopia is pivotal for the development of targeted interventions, moving the focus of myopia management beyond optical correction towards disease-modifying strategies."

Journal • Review • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • MMP2

Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (clinicaltrials.gov) - P=N/A | N=74 | Not yet recruiting | Sponsor: Hongyan Wu

New trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Toward Reliable Individual-Level Optical Coherence Tomography Biomarkers in Multiple Sclerosis: A Protocol Comparison Study (ECTRIMS 2025) - "At each visit, five macular scan protocols were performed in randomized order: standard (49 lines, high-speed [HS], automated real-time tracking [ART] 9), high-ART (49 lines, HS, ART 50), high-lines (97 lines, HS, ART 9), high-resolution (49 lines, high-resolution [HR], ART 9), and maximum (97 lines, HR, ART 50)... All evaluated OCT protocols demonstrated excellent test-retest and inter-protocol reliability in measuring GCIPL thickness. Balancing reliability with time efficiency, high-lines and high-resolution protocols offer an optimal compromise between data quality and practical feasibility. Standardized acquisition parameters are strongly recommended to ensure reproducibility and comparability of findings across studies."

Biomarker • Clinical • CNS Disorders • Multiple Sclerosis

Amelioration of intestinal ischemia reperfusion injury by diacerein via regulation of inflammasome/caspase-1/IL-1β and Wnt/β-catenin pathways in juvenile rats. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This effect of DIA is greatly attributed to its pharmacological properties including IL-1β antagonist effect, anti-oxidant, anti-apoptotic, and anti-inflammatory properties. Thus, DIA could be considered as an adjuvant future medical therapy for those cases of II/R."

Journal • Preclinical • Cardiovascular • Reperfusion Injury • CASP3 • IL1B

Dissolvable microneedle-assisted transdermal administration of diacerein nanoparticles achieved satisfactory therapeutic effects in tendon-bone insertion repair by reducing oxidative stress and inflammation. (PubMed, Mater Today Bio) - "These findings suggest that DMN/PLGA@Dia is capable of promoting tendon-bone insertion repair by alleviating oxidative stress and regulating the immune microenvironment strategies. Simple DMN/PLGA@Dia may be an effective and safe nanomedicine delivery system for tendon-bone insertion repair."

Journal • Inflammation

An LC-MS Method to Quantify Rhein and Its Metabolites in Plasma: Application to a Pharmacokinetic Study in Rats. (PubMed, Metabolites) - "The pharmacokinetic study demonstrated that diacerein is swiftly metabolized into Rhein, and then Rhein subsequently undergoes glucuronidation, forming detectable concentrations of Rhein-G1 and Rhein-G2 in plasma. This new LC-MS/MS method proved to be both sensitive and selective, allowing for pharmacokinetic studies in rats."

Journal • PK/PD data • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology

Injectable oxidized hyaluronic acid/quaternized chitosan hydrogel encapsulated with diacerein microsphere for improved osteoarthritis treatment. (PubMed, Int J Biol Macromol) - "The DIA-MS@gel provided continuous drug release for over 31 days within the rabbit joint cavity, potentially reducing administration frequency, attenuating inflammation, and promoting bone tissue regeneration. Furthermore, the DIA-MS@gel exhibited excellent biocompatibility, suggesting its potential as a practical clinical approach for managing OA."

Journal • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

Involvement of IL-6/JAK/STAT3/SOCS3, SIRT1, and Cytoglobin Signaling in Diacerein Protective Effect against Intestinal Injury Induced by Methotrexate. (PubMed, J Biochem Mol Toxicol) - "Furthermore, DIA inhibited intestinal apoptotic alterations by reducing cleaved caspase-3 protein expression. These results suggest that DIA, in a dose-dependent manner, could be an effective treatment for reducing intestinal toxicity by MTX via exerting an antioxidant effect, anti-inflammatory properties, and antiapoptotic activity with possible involvement of NF-κBp65, IL-6/JAK1/STAT3/SOCS3, SIRT1, and cytoglobin signaling."

Journal • Inflammation • Inflammatory Bowel Disease • Pain • CASP3 • IL6 • JAK1 • SOCS3 • STAT3 • TNFA

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (clinicaltrials.gov) - P2/3 | N=80 | Recruiting | Sponsor: TWi Biotechnology, Inc. | Trial completion date: Mar 2026 ➔ Jan 2027 | Trial primary completion date: Aug 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • KRT14 • KRT5

Diacerein counteracts amiodarone‑induced hepatotoxicity in rats via targeting TLR4/NF-kB/NLRP3 pathways. (PubMed, Toxicol Mech Methods) - "Those findings suggest that DCN exerts its hepatoprotective effects through its anti-oxidant activity, modulation of TLR4/NF-κB/NLRP3 inflammatory pathways, and reduction of apoptosis. These results provide new insights into potential therapeutic strategies for managing AMIO-induced hepatotoxicity, warranting further investigation into the underlying molecular mechanisms of DCN's protective effects."

IO biomarker • Journal • Preclinical • CASP3 • IL1B • NLRP3 • TLR4 • TNFA

Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang (clinicaltrials.gov) - P2/3 | N=34 | Completed | Sponsor: Universitas Sriwijaya

New P2/3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring the antibacterial and anti-biofilm properties of Diacerein against methicillin-resistant Staphylococcus aureus. (PubMed, Front Microbiol) - "The MIC and MBC of DIA against MRSA were 32 μg/mL and 128 μg/mL, respectively, and synergistic antibacterial effects when combined with ampicillin. In summary, DIA has antibacterial and anti-biofilm activities against MRSA and does not easily induce resistance. Its antibacterial mechanisms may involve multiple aspects, including bacterial protein synthesis, energy metabolism."

Journal • Infectious Disease • Rheumatology

Diacerein's Antiproliferative Effects Alone and with 5-Fluorouracil in an Ehrlich Solid Tumour Model: Molecular Docking, Molecular Dynamics Simulation Studies, and Experimental Verification. (PubMed, Eur J Pharmacol) - "Furthermore, diacerein and 5-FU combination significantly suppressed oxidative stress, inhibited AKT phosphorylation, decreased downstream inflammation (NF-κB, TNF-α, IL-1β), and increased apoptosis by modulating Bax, Bcl2, P53, and caspase-3 levels in tumor tissues. In conclusion, by inhibiting the AKT/NF-κB axis, diacerein and 5-FU combination showed possible antiproliferative effectiveness in the EST model."

Journal • Breast Cancer • Oncology • Solid Tumor • AKT1 • BAX • BCL2 • CASP3 • IL1B • TNFA

Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies. (PubMed, Drugs) - "This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs. Beyond the evidence here reported, the limitations of this research highlight the urgent need of a reporting guideline for post-marketing safety surveillance studies. Importantly, real-life safety surveillance of anti-OA medications should be strengthened with large cohort studies with control groups, and results should be disaggregated by disease populations for drugs common to several conditions."

Journal • P4 data • Review • Allergy • Cardiovascular • Gastrointestinal Disorder • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Rheumatology

Pain sensation and emotion induced by aromatase inhibitors: a new mouse model. (PubMed, Pain) - "We administered different doses of letrozole to young, artificially menopausal female C57BL/6J mice and assessed pain sensation, emotion-related behaviors, and exercise endurance to identify the optimal AI dose and intervention period. Administration of diacerein partially alleviated pain-related behaviors. This model provides a valuable platform for exploring the cellular and molecular mechanisms of AI treatment and evaluating potential therapeutic interventions."

Journal • Preclinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Mood Disorders • Oncology • Pain • Psychiatry • Solid Tumor • IFNG • IL1B • IL6 • TNFA

Protective effects of diacerein against quinolinic acid-induced Huntington's disease-like symptoms in adult zebrafish by targeting GSK-3β signalling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "route as a toxin on the day 0, and diacerein (25 and 50 mg/kg) as treatment and tetrabenazine as standard were used for 14 days. Diacerein enhances motor function, modulates neurotransmitter levels, diminishes oxidative stress markers, controls the generation of inflammatory cytokines, and inhibits GSK-3β activity. Furthermore, diacerein improves the neurotoxicity and neurobehavioral impairments in adult zebra fish with Huntington's disease-like symptoms caused by quinolinic acid."

Journal • CNS Disorders • Huntington's Disease • Mood Disorders • Movement Disorders • Pain • Psychiatry • CAT • GSK3B • IL17A • IL1B • TNFA

FTO aggravates podocyte injury and diabetic nephropathy progression via m6A-dependent stabilization of ACC1 mRNA and promoting fatty acid metabolism. (PubMed, Biochem Pharmacol) - "Furthermore, we confirmed that two selective FTO demethylation inhibitors meclofenamic acid (MA) and diacerein (DIA) administration effectively ameliorated lipotoxicity-induced podocyte injury, evidenced by restored autophagy, inhibition of apoptosis and inflammation, as well as mitigating endoplasmic reticulum stress (ERS) and mitochondrial damage both in vitro and vivo model of DN...ACC1 was identified as a direct FTO target in which FTO stabilizes ACC1 mRNA with the mediation of YTH domain-containing family protein 2 (YTHDF2) in an m6A-dependent manner using m6A RNA immunoprecipitation-quantitative real-time PCR (MeRIP-qPCR) and dual-luciferase reporter gene assays. Collectively, our findings demonstrate an important role of FTO mediated-m6A modification of ACC1 contributed to s lipotoxicity-mediated injury of DN podocytes, which provide fresh insights into the therapeutic strategies for DN."

Journal • Diabetic Nephropathy • Genetic Disorders • Inflammation • Nephrology • Obesity • Renal Disease • ACACA • FTO • YTHDF2

Structural and Mechanistic Insights into the Main Protease (Mpro) Dimer Interface Destabilization Inhibitor: Unveiling New Therapeutic Avenues against SARS-CoV-2. (PubMed, Biochemistry) - "This study identified six highly efficacious antiviral SARS-CoV-2 compounds (WIN-62577, KT185, bexarotene, ledipasvir, diacerein, and simepervir) using structure-based virtual screening of compound libraries against Mpro. Minocycline binds to an allosteric site, revealing residues critical for the loss of protease activity due to destabilization of molecular interactions at the dimeric interface, which are crucial for the proteolytic activity of Mpro. The study suggests that the binding of minocycline to the allosteric site may play a role in Mpro dimer destabilization and direct the rational design of minocycline derivatives as antiviral drugs."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expression. (PubMed, J Dermatol) - "We also provide evidence that diacerein treatment of patient keratinocytes results in a downregulation of MMP-9 expression, accompanied by a reduction in their ability to degrade a fibrinogen matrix. These data characterize diacerein as a potential candidate for improving wound healing in RDEB through its impact on inflammatory as well as epithelial cells."

Journal • Oncology • Squamous Cell Carcinoma • COL7A1 • MMP9